SCHEMBL3079414

SCHEMBL3079414

COC(=O)C1c2ccc(OCc3ccc(OC)c(C)c3)cc2CCN1C(=O)OCC(C)C

nearest known ligand 0.50

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 18/20 0.50
S1PR1 P21453 1/20 0.43
ACACB O00763 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3072401 0.94 GHSR (0.52) GHSRS1PR1
SCHEMBL3080137 0.93 GHSR (0.51) GHSRACACB
SCHEMBL3074567 0.91 GHSR (0.49) GHSRACACB
SCHEMBL3075934 0.91 GHSR (0.55) GHSR
SCHEMBL3069146 0.90 GHSR (0.50) GHSR
SCHEMBL3075510 0.90 GHSR (0.55) GHSR
SCHEMBL3074264 0.88 GHSR (0.55) GHSR
SCHEMBL3071279 0.88 GHSR (0.53) GHSR
SCHEMBL3065310 0.88 GHSR (0.53) GHSR
SCHEMBL3065189 0.87 GHSR (0.51) GHSRACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951675-B1 TETRAHYDROISOQUINOLINE AS LXR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2013-03-20 EP disclosed
US-7790745-B2 Tetrahydroisoquinoline LXR Modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2010-09-07 US disclosed
US-20070093523-A1 Tetrahydroisoquinoline LXR modulators BRISTOL-MYERS SQUIBB COMPANY 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093523-A1 Tetrahydroisoquinoline LXR modulators NR1H2, NR1H3, NR1I2 GHSR 351/4885S1PR1 336/4885ACACB 555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.